Your browser doesn't support javascript.
loading
Nose-to-Brain Targeted Delivery of Donepezil Hydrochloride via Novel Hyaluronic Acid-Doped Nanotransfersomes for Alzheimer's Disease Mitigation.
Salem, Heba F; Aboud, Heba M; Abdellatif, Mostafa M; Abou-Taleb, Heba A.
Afiliação
  • Salem HF; Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Beni-Suef University, Beni-Suef, Egypt.
  • Aboud HM; Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Beni-Suef University, Beni-Suef, Egypt. Electronic address: heba.aboud@pharm.bsu.edu.eg.
  • Abdellatif MM; Department of Pharmaceutics, Faculty of Pharmacy, Nahda University, Beni-Suef, Egypt.
  • Abou-Taleb HA; Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Merit University, Sohag, Egypt.
J Pharm Sci ; 113(7): 1934-1945, 2024 Jul.
Article em En | MEDLINE | ID: mdl-38369023
ABSTRACT
Alzheimer's disease is the most serious neurodegenerative disorder characterized by cognitive and memorial defects alongside deterioration in behavioral, thinking and social skills. Donepezil hydrochloride (DPZ) is one of the current two FDA-approved cholinesterase inhibitors used for the management of Alzheimer's disease. The current study aimed to formulate hyaluronic acid-coated transfersomes containing DPZ (DPZ-HA-TFS) for brain delivery through the intranasal pathway to surpass its oral-correlated GIT side effects. DPZ-HA-TFS were produced using a thin film hydration method and optimized with a 24 factorial design. The influence of formulation parameters on vesicle diameter, entrapment, cumulative release after 8 h, and ex vivo nasal diffusion after 24 h was studied. The optimal formulation was then evaluated for morphology, stability, histopathology and in vivo biodistribution studies. The optimized DPZ-HA-TFS formulation elicited an acceptable vesicle size (227.5 nm) with 75.83% entrapment efficiency, 37.94% cumulative release after 8 h, 547.49 µg/cm2 permeated through nasal mucosa after 24 h and adequate stability. Histopathological analysis revealed that the formulated DPZ-HA-TFS was nontoxic and tolerable for intranasal delivery. Intranasally administered DPZ-HA-TFS manifested significantly superior values for drug targeting index (5.08), drug targeting efficiency (508.25%) and direct nose-to-brain transport percentage (80.32%). DPZ-HA-TFS might be deemed as a promising intranasal nano-cargo for DPZ cerebral delivery to tackle Alzheimer's disease safely, steadily and in a non-invasive long-term pattern.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Encéfalo / Administração Intranasal / Inibidores da Colinesterase / Doença de Alzheimer / Donepezila / Ácido Hialurônico / Mucosa Nasal Limite: Animals Idioma: En Revista: J Pharm Sci Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Egito

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Encéfalo / Administração Intranasal / Inibidores da Colinesterase / Doença de Alzheimer / Donepezila / Ácido Hialurônico / Mucosa Nasal Limite: Animals Idioma: En Revista: J Pharm Sci Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Egito